Anti-IL-21 monoclonal antibody combined with liraglutide effectively reverses established hyperglycemia in mouse models of type 1 diabetes
- PMID: 28711285
- DOI: 10.1016/j.jaut.2017.07.006
Anti-IL-21 monoclonal antibody combined with liraglutide effectively reverses established hyperglycemia in mouse models of type 1 diabetes
Abstract
Immunotherapy for type 1 diabetes (T1D) has previously focused on suppressing the autoimmune response against pancreatic beta cells to preserve endogenous insulin production and regulate glucose levels. With increased attention toward combination therapy strategies, studies indicate the multifunctional cytokine interleukin-21 (IL-21) may be a suitable target as an immuno-modulatory arm, while glucagon-like peptide-1 receptor (GLP-1R) agonists may be appropriate as a beta cell protective arm in combination therapy for T1D. We report here that treatment with anti-IL-21 monoclonal antibody delays diabetes onset in the spontaneous non-obese diabetic (NOD) and NOD.scid adoptive transfer models, while its effect in reversing recent-onset hyperglycemia is limited. However, the combination of anti-IL-21 plus the GLP-1R agonist liraglutide is effective in reversing established disease compared to either monotherapy in both the NOD and rat insulin promotor-lymphocytic choriomeningitis virus glycoprotein (RIP-LCMV-GP) models of autoimmune diabetes. Enhanced efficacy is particularly evident in severely hyperglycemic mice, with return to normoglycemia remaining stable for the majority of mice even after therapy is withdrawn. Importantly, increased beta cell proliferation does not appear to be the predominant mechanism. In conclusion, combination therapy with anti-IL-21 and liraglutide is able to consistently reverse disease in mouse models of T1D. The observed effects rival the most effective experimental disease-modifying treatments tested in preclinical studies.
Keywords: Combination therapy; GLP-1; IL-21; Immunotherapy; Mouse models; Type 1 diabetes.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Similar articles
-
IL-2 immunotherapy reveals potential for innate beta cell regeneration in the non-obese diabetic mouse model of autoimmune diabetes.PLoS One. 2013 Oct 24;8(10):e78483. doi: 10.1371/journal.pone.0078483. eCollection 2013. PLoS One. 2013. PMID: 24205242 Free PMC article.
-
A Preclinical Consortium Approach for Assessing the Efficacy of Combined Anti-CD3 Plus IL-1 Blockade in Reversing New-Onset Autoimmune Diabetes in NOD Mice.Diabetes. 2016 May;65(5):1310-6. doi: 10.2337/db15-0492. Epub 2015 Dec 30. Diabetes. 2016. PMID: 26718498 Free PMC article.
-
Interleukin-21-dependent modulation of T cell antigen receptor reactivity towards low affinity peptide ligands in autoreactive CD8(+) T lymphocytes.Cytokine. 2016 Sep;85:83-91. doi: 10.1016/j.cyto.2016.06.011. Epub 2016 Jun 11. Cytokine. 2016. PMID: 27300756
-
Immunotherapy of type 1 diabetes.Arch Immunol Ther Exp (Warsz). 2008 Jul-Aug;56(4):227-36. doi: 10.1007/s00005-008-0025-2. Epub 2008 Jul 29. Arch Immunol Ther Exp (Warsz). 2008. PMID: 18726144 Review.
-
Immunomodulation and regeneration of islet Beta cells by cytokines in autoimmune type 1 diabetes.J Interferon Cytokine Res. 2011 Oct;31(10):711-9. doi: 10.1089/jir.2011.0025. Epub 2011 Aug 18. J Interferon Cytokine Res. 2011. PMID: 21851268 Review.
Cited by
-
Liraglutide Attenuates Hepatic Oxidative Stress, Inflammation, and Apoptosis in Streptozotocin-Induced Diabetic Mice by Modulating the Wnt/β-Catenin Signaling Pathway.Mediators Inflamm. 2023 Jan 29;2023:8974960. doi: 10.1155/2023/8974960. eCollection 2023. Mediators Inflamm. 2023. PMID: 36756089 Free PMC article.
-
Preclinical models for Type 1 Diabetes Mellitus - A practical approach for research.Int J Med Sci. 2023 Oct 2;20(12):1644-1661. doi: 10.7150/ijms.86566. eCollection 2023. Int J Med Sci. 2023. PMID: 37859703 Free PMC article. Review.
-
Janus kinase and signal transducer and activator of transcription inhibitors in type 1 diabetes and immune checkpoint-related diabetes: current status and future perspectives.Front Immunol. 2025 Jun 4;16:1571247. doi: 10.3389/fimmu.2025.1571247. eCollection 2025. Front Immunol. 2025. PMID: 40534861 Free PMC article. Review.
-
Emerging immunotherapies for autoimmune kidney disease.Hum Vaccin Immunother. 2019;15(4):876-890. doi: 10.1080/21645515.2018.1555569. Epub 2019 Jan 16. Hum Vaccin Immunother. 2019. PMID: 30550361 Free PMC article. Review.
-
Autoimmunity in 2017.Clin Rev Allergy Immunol. 2018 Dec;55(3):239-253. doi: 10.1007/s12016-018-8699-7. Clin Rev Allergy Immunol. 2018. PMID: 30051260 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous